Meeting
2023 ASCO Breakthrough
Explainable machine learning to inform real-world evidence: A case study on small cell lung cancer survival analysis.
Authors
Luca Marzano
KTH Royal Institute of Technology, Stockholm, Sweden
Luca Marzano , Adam S. Darwich , Asaf Dan , Salomon Tendler , Jayanth Raghotama , Rolf Lewensohn , Luigi De Petris , Sebastiaan Meijer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Gastrointestinal Cancer,Gynecologic Cancer,Head and Neck Cancer,Quality of Care,Genetics/Genomics/Multiomics,Healthcare Equity and Access to Care,Healthtech Innovations,Models of Care and Care Delivery,Population Health,Viral-Mediated Malignancies
Sub Track
Real-World Evidence/Real-World Data
Citation
JCO Global Oncology 9, 2023 (suppl 1; abstr 113)
DOI
10.1200/GO.2023.9.Supplement_1.113
Abstract #
113
Poster Bd #
G8
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Predicting efficacy in patients with locally advanced (LA)/metastatic urothelial carcinoma (mUC) treated with avelumab using machine learning and explainability approaches.
First Author: Patrizia Giannatempo
Poster
2023 ASCO Genitourinary Cancers Symposium
Local and systemic therapies for renal cell carcinoma with brain metastases: A single-institution series.
First Author: Teja Ganta
Poster
2023 ASCO Genitourinary Cancers Symposium
Evaluation of eligibility criteria in contemporary renal cell carcinoma based on ASCO-FCR recommendations.
First Author: Sweta R. Prajapati
Poster
2019 ASCO Annual Meeting
ml-RECIST: Machine learning to estimate RECIST in patients with NSCLC treated with PD-(L)1 blockade.
First Author: Kathryn Cecilia Arbour